These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 683271)

  • 1. Transfusions and erythropoiesis in beta-thalassemia.
    Celada A
    N Engl J Med; 1978 Aug; 299(7):360. PubMed ID: 683271
    [No Abstract]   [Full Text] [Related]  

  • 2. Current concepts in the overall management of thalassemia.
    Propper RD
    Ann N Y Acad Sci; 1980; 344():375-83. PubMed ID: 6930877
    [No Abstract]   [Full Text] [Related]  

  • 3. Iron balance in thalassemia.
    Cazzola M; Finch CA
    Prog Clin Biol Res; 1989; 309():93-100. PubMed ID: 2675109
    [No Abstract]   [Full Text] [Related]  

  • 4. Erythropoiesis and the effect of transfusion in homozygous beta-thalassemia.
    Cavill I; Ricketts C; Jacobs A; Letsky E
    N Engl J Med; 1978 Apr; 298(14):776-8. PubMed ID: 628411
    [No Abstract]   [Full Text] [Related]  

  • 5. Iron loading in beta-thalassaemia.
    Cazzola M; Alessandrino P; Barosi G; Orlandi E; Ascari E
    Lancet; 1980 Jan; 1(8161):204. PubMed ID: 6101656
    [No Abstract]   [Full Text] [Related]  

  • 6. Relation between erythropoiesis and bone metabolism in thalassemia.
    Pootrakul P; Hungsprenges S; Fucharoen S; Baylink D; Thompson E; English E; Lee M; Burnell J; Finch C
    N Engl J Med; 1981 Jun; 304(24):1470-3. PubMed ID: 7231478
    [No Abstract]   [Full Text] [Related]  

  • 7. Interaction of Transfusion and Iron Chelation in Thalassemias.
    Porter JB; Garbowski MW
    Hematol Oncol Clin North Am; 2018 Apr; 32(2):247-259. PubMed ID: 29458730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferroportin expression and regulation in non-transfusion dependent thalassemia.
    Sonzogni L; Ronzoni L; Graziadei G; Cappellini MD
    Blood Cells Mol Dis; 2016 May; 58():26-8. PubMed ID: 27067485
    [No Abstract]   [Full Text] [Related]  

  • 9. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.
    Porter JB; Cappellini MD; Kattamis A; Viprakasit V; Musallam KM; Zhu Z; Taher AT
    Br J Haematol; 2017 Jan; 176(2):288-299. PubMed ID: 27917462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morbidities in non-transfusion-dependent thalassemia.
    Saliba AN; Taher AT
    Ann N Y Acad Sci; 2016 Mar; 1368(1):82-94. PubMed ID: 27186941
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Iron metabolism and iron chelation in the thalassaemia disorders.
    Pippard MJ
    Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383
    [No Abstract]   [Full Text] [Related]  

  • 12. Iron overload in a non-transfused patient with thalassaemia intermedia.
    Celada A
    Scand J Haematol; 1982 Feb; 28(2):169-74. PubMed ID: 7089477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Getting the iron out: preventing and treating heart failure in transfusion-dependent thalassemia.
    Jabbar DA; Davison G; Muslin AJ
    Cleve Clin J Med; 2007 Nov; 74(11):807-10, 813-6. PubMed ID: 18020000
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro globin chain synthesis after blood transfusion in Sicilian homozygous beta thalassemia.
    Russo G; Musumeci S; Schilirò G; Pizzarelli G; Fischer A; Romeo MA
    Ann N Y Acad Sci; 1980; 344():305-13. PubMed ID: 6930871
    [No Abstract]   [Full Text] [Related]  

  • 15. New therapeutic targets in transfusion-dependent and -independent thalassemia.
    Cappellini MD; Motta I
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):278-283. PubMed ID: 29222267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-Transfusion-Dependent Thalassemia: An Update on Complications and Management.
    Sleiman J; Tarhini A; Bou-Fakhredin R; Saliba AN; Cappellini MD; Taher AT
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29316681
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New approaches to the transfusion management of thalassemia.
    Propper RD; Button LN; Nathan DG
    Blood; 1980 Jan; 55(1):55-60. PubMed ID: 7350942
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin.
    Garbowski MW; Evans P; Vlachodimitropoulou E; Hider R; Porter JB
    Haematologica; 2017 Oct; 102(10):1640-1649. PubMed ID: 28642302
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma neutrophil gelatinase-associated lipocalin levels are markedly increased in patients with non-transfusion-dependent thalassemia: Lack of association with markers of erythropoiesis, iron metabolism and renal function.
    Patsaoura A; Tatsi E; Margeli A; Kanavaki I; Delaporta P; Kyriakopoulou D; Kouraklis-Symeonidis A; Kattamis A; Papassotiriou I
    Clin Biochem; 2014 Aug; 47(12):1060-4. PubMed ID: 24721683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pathophysiology and treatment of iron overload in thalassemia patients in tropical countries.
    Marx JJ
    Adv Exp Med Biol; 2003; 531():57-68. PubMed ID: 12916781
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.